{"success":true,"data":{"pressRelease":{"id":"161198","rtpr_id":"nGNE7s8rGp-20261006","ticker":"ORNBV","exchange":"Nasdaq Helsinki","all_tickers":["ORNBV"],"title":"REG-Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market","author":"Globe Newswire","published_at":"2026-10-06T06:00:00.120Z","article_body":"ORION CORPORATION \nPRESS RELEASE \n6 OCTOBER 2026 at 9.00 EEST\n        \n\nOrion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab\nbiosimilar for European market\n\nOrion Corporation (“Orion Pharma”) and Qilu Pharma Europe (“Qilu”)\nhave entered into an agreement to commercialise intravenous (IV) pembrolizumab\nbiosimilar in Europe. Pembrolizumab is an immune checkpoint inhibitor which is\nused to treat various cancers. Qilu is currently developing IV pembrolizumab.\n\nUnder the terms of the agreement, Orion Pharma will gain exclusive right to\ndistribute, market and sell Qilu’s IV pembrolizumab biosimilar in Europe.\nQilu will supply the product to Orion Pharma, and is entitled to receive a\nshare of profits from Orion Pharma as well as certain development, regulatory\nand sales milestone payments.\n\n“We are pleased to expand our strategic partnership with Qilu,” said Satu\nAhomäki, EVP Generics and Consumer Health, Orion Pharma. “With this\nagreement, we are one step closer to reaching our division’s long-term\ntargets and strategic goals, and to creating broader access to affordable\nquality medicines.”\n\nOrion Corporation\n\nContact person:\nSatu Ahomäki, EVP, Generics and Consumer Health, Orion Pharma\n\ntel. +358 10 426 7616\n\n                        \n                        \n\nPublisher:\nOrion Corporation\nCommunications\nOrionintie 1A, FI-02200 Espoo, Finland\nhttp://www.orionpharma.com\n\nOrion Pharma is a globally operating Nordic pharmaceutical company – a\nbuilder of well-being for over a hundred years. We develop, manufacture and\nmarket human and veterinary pharmaceuticals as well as active pharmaceutical\ningredients, combining our trusted expertise with continuous innovation. We\nhave an extensive portfolio of proprietary and generic medicines and consumer\nhealth products. The core therapy areas of our pharmaceutical R&D are oncology\nand pain. Proprietary products developed by us are used to treat cancer,\nrespiratory diseases and neurological diseases, among others. In 2025 our net\nsales amounted to EUR 1,890 million, and we employ about 4,000 professionals\nworldwide, dedicated to building well-being.","article_body_html":"","raw_payload":{"data":{"id":"nGNE7s8rGp-20261006","title":"REG-Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market","author":"Globe Newswire","ticker":"ORNBV","created":"2026-10-06T06:00:00.120Z","tickers":["ORNBV"],"exchange":"Nasdaq Helsinki","article_body":"ORION CORPORATION \nPRESS RELEASE \n6 OCTOBER 2026 at 9.00 EEST\n        \n\nOrion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab\nbiosimilar for European market\n\nOrion Corporation (“Orion Pharma”) and Qilu Pharma Europe (“Qilu”)\nhave entered into an agreement to commercialise intravenous (IV) pembrolizumab\nbiosimilar in Europe. Pembrolizumab is an immune checkpoint inhibitor which is\nused to treat various cancers. Qilu is currently developing IV pembrolizumab.\n\nUnder the terms of the agreement, Orion Pharma will gain exclusive right to\ndistribute, market and sell Qilu’s IV pembrolizumab biosimilar in Europe.\nQilu will supply the product to Orion Pharma, and is entitled to receive a\nshare of profits from Orion Pharma as well as certain development, regulatory\nand sales milestone payments.\n\n“We are pleased to expand our strategic partnership with Qilu,” said Satu\nAhomäki, EVP Generics and Consumer Health, Orion Pharma. “With this\nagreement, we are one step closer to reaching our division’s long-term\ntargets and strategic goals, and to creating broader access to affordable\nquality medicines.”\n\nOrion Corporation\n\nContact person:\nSatu Ahomäki, EVP, Generics and Consumer Health, Orion Pharma\n\ntel. +358 10 426 7616\n\n                        \n                        \n\nPublisher:\nOrion Corporation\nCommunications\nOrionintie 1A, FI-02200 Espoo, Finland\nhttp://www.orionpharma.com\n\nOrion Pharma is a globally operating Nordic pharmaceutical company – a\nbuilder of well-being for over a hundred years. We develop, manufacture and\nmarket human and veterinary pharmaceuticals as well as active pharmaceutical\ningredients, combining our trusted expertise with continuous innovation. We\nhave an extensive portfolio of proprietary and generic medicines and consumer\nhealth products. The core therapy areas of our pharmaceutical R&D are oncology\nand pain. Proprietary products developed by us are used to treat cancer,\nrespiratory diseases and neurological diseases, among others. In 2025 our net\nsales amounted to EUR 1,890 million, and we employ about 4,000 professionals\nworldwide, dedicated to building well-being."},"type":"article","timestamp":"2026-10-06T06:00:00.256069802Z","server_sent_at_ms":1791266400256},"received_at":"2026-10-06T06:00:00.307Z","source_url":null},"analysis":{"id":"149743","press_release_id":"161198","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["product still in development by Qilu; no launch timeline disclosed","financial terms of the agreement not disclosed"],"eventType":"partnership","narrative":"Orion Corporation and Qilu Pharma Europe entered an agreement for Orion to exclusively distribute, market and sell Qilu's IV pembrolizumab biosimilar across Europe.\n\nPembrolizumab is an immune checkpoint inhibitor used to treat various cancers; Qilu is currently developing the IV biosimilar and will supply the product while receiving a share of profits plus development, regulatory and sales milestone payments.\n\nThe deal supports Orion's Generics and Consumer Health division's long-term targets and adds a high-value oncology biosimilar to its portfolio, though financial terms and timing were not disclosed.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Orion locks up exclusive EU rights to a Keytruda-class biosimilar, deepening its oncology generics push."},"keyFigures":{"customDimensions":{"employees":"about 4,000","net_sales_2025_eur":"EUR 1,890 million"}},"quotedText":"We are pleased to expand our strategic partnership with Qilu","namedEntities":{"people":[{"name":"Satu Ahomäki","role":"EVP Generics and Consumer Health, Orion Pharma"}],"products":["IV pembrolizumab biosimilar","pembrolizumab"],"companies":[{"name":"Orion Corporation","ticker":"ORNBV","relationship":"filer"},{"name":"Qilu Pharma Europe","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Exclusive European commercialization rights for a pembrolizumab biosimilar (Keytruda-class oncology asset) expand Orion's generics/pipeline, but financial terms are undisclosed and the product is still in development."},"tickerRelevance":{"others":[],"primary":"ORNBV"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"mid-cap European pharma","eventGravity":"commercialization partnership for major biosimilar","sectorWeight":"pharma-biosimilars","financialTermsDisclosed":false}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Orion Corporation and Qilu Pharma Europe entered an agreement for Orion to exclusively distribute, market and sell Qilu's IV pembrolizumab biosimilar across Europe.\n\nPembrolizumab is an immune checkpoint inhibitor used to treat various cancers; Qilu is currently developing the IV biosimilar and will supply the product while receiving a share of profits plus development, regulatory and sales milestone payments.\n\nThe deal supports Orion's Generics and Consumer Health division's long-term targets and adds a high-value oncology biosimilar to its portfolio, though financial terms and timing were not disclosed.","key_figures":{"customDimensions":{"employees":"about 4,000","net_sales_2025_eur":"EUR 1,890 million"}},"named_entities":{"people":[{"name":"Satu Ahomäki","role":"EVP Generics and Consumer Health, Orion Pharma"}],"products":["IV pembrolizumab biosimilar","pembrolizumab"],"companies":[{"name":"Orion Corporation","ticker":"ORNBV","relationship":"filer"},{"name":"Qilu Pharma Europe","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T06:00:05.902Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap European pharma","eventGravity":"commercialization partnership for major biosimilar","sectorWeight":"pharma-biosimilars","financialTermsDisclosed":false}},"durationMs":5559,"modelName":"glm-5.3-flashx"}}